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Abstract 
 
Background and aims: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) performed before 
curative therapy for hepatocellular carcinoma (HCC) can distinguish between 
intrahepatic distant recurrence and hypervascularization. We aimed to retrospectively 
evaluate the presence of non-hypervascular hypointense nodules on hepatobiliary phase 
images (HBPI) from Gd-EOB-DTPA-enhanced MRI as a risk factor of the intrahepatic 
distant recurrence of early-stage HCC following radiofrequency ablation (RFA). 
Methods: A total of 132 patients who underwent preprocedural Gd-EOB-DTPA-
enhanced MRI followed by initial RFA were retrospectively analyzed. Post-RFA 
intrahepatic distant recurrence, which excluded the hypervascularization of non-
hypervascular hypointense nodules detected by preprocedural Gd-EOB-DTPA-enhanced 
MRI, was evaluated according to the presence of non-hypervascular hypointense nodules 
on preprocedural Gd-EOB-DTPA-enhanced MRI. 
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Results: Intrahepatic distant recurrence rates following RFA were higher in patients with 
non-hypervascular hypointense nodules (1-year: 22.5, 2-year: 52.1%, 5-year: 89.1%) 
compared with in patients without non-hypervascular hypointense nodules (1-year: 7.0, 
2-year: 28.8%, 5-year: 48.7%). The presence of non-hypervascular hypointense nodules 
was associated with markedly increased cumulative recurrence rates of both identical and 
different subsegment intrahepatic distant recurrence, being an independent risk factor for 
post-RFA identical and different subsegment intrahepatic distant recurrence (identical: 
HR = 2.365, P = 0.027. different: HR = 3.276, P <0.001). 
Conclusion: The presence of non-hypervascular hypointense nodules on HBPI from Gd-
EOB-DTPA-enhanced MRI obtained prior to RFA is an important predictive factor of 
intrahepatic distant recurrence following RFA of HCC. 
 
Keywords: hepatocellular carcinoma; Gd-EOB-DTPA-enhanced MRI; non-
hypervascular hypointense nodule; radiofrequency ablation; recurrence; 
hypervascularization 
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Introduction 
 
Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause 
of cancer-related deaths worldwide, with about 667,000 new cases per annum [1]. 
Although surveillance systems of high-risk populations, radiological examination, and 
treatment methods have been developed and improved, most HCC patients suffer from 
the relapse even after curative therapy, resulting in a poor prognosis [2-4].   
The newly introduced magnetic resonance imaging (MRI) contrast agent, 
gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA), has 
enabled the concurrent assessment of tumor vascularity and unique hepatocyte specific 
contrast during the acquisition of hepatobiliary phase images (HBPI) [5-9]. Gadoxetic 
acid is taken up by organic anion transporting polypeptide (OATP) B1/8 transporters into 
the hepatocytes [10-11]. OATP B1/8 expression gradually decreases during the process 
of hepatocarcinogenesis. Thus, borderline hepatocellular nodules that have potential to 
progress to overt HCC appear as non-hypervascular hypointense nodules on the HBPI 
(i.e., hypervascularization) [12, 13]. Hypervascularization is a new concept of recurrence 
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and proposed after the approval of Gd-EOB-DTPA-enhanced MRI. 
Recent articles demonstrated the presence of non-hypervascular hypointense nodules 
on HBPI from Gd-EOB-DTPA-enhanced MRI observed prior to curative therapy 
conferred a high risk of post-curative therapy recurrence [14,15]. Moreover, these reports 
may indicate that the livers of patients with non-hypervascular hypointense nodules have 
a high potential of carcinogenesis. However, these reports did not identify the recurrence 
type by distinguishing between intrahepatic distant recurrence and hypervascularization. 
Because non-hypervascular hypointense nodules have a high probability of 
hypervascularization, the carcinogenetic potential of liver parenchyma cannot be 
estimated without classifying intrahepatic distant recurrence and hypervascularization. 
Furthermore, information on intrahepatic distant recurrence in patients with or without 
non-hypervascular hypointense nodules are required to consider treatment and follow-up 
strategies for patients with non-hypervascular hyponintense nodules along with 
hypervascular HCC. It remains controversial whether the presence of non-hypervascular 
hypointense nodules is a risk factor of intrahepatic distant recurrence after curative 
therapy. The aim of this study was to retrospectively evaluate the impact of the presence 
7 
 
of non-hypervascular hypointense nodules on HBPI of Gd-EOB-DTPA enhanced MRI on 
intrahepatic distant recurrence after radiofrequency ablation (RFA) of early-stage HCC. 
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Patients and Methods 
 
Patients 
The research ethics committee of our institution approved this study (No. 2,148), and the 
requirement for the informed consent of treatment was waived. Medical records were 
retrieved for patients with HCC treated at our institution.  
Patients enrolled in this study were selected using the following inclusion criteria at 
their initial RFA: (1) the presence of histologically confirmed or clinically diagnosed 
HCC (fulfilling the criteria for lesions with typical imaging) [16], (2) presence of early-
stage HCC (single hypervascular HCC lesion of ≤ 50 mm or ≤ 3 hypervascular HCC 
lesions of ≤ 30 mm, without macrovascular invasion or extrahepatic metastasis), (3) 
Child–Pugh A or B, and (4) Gd-EOB-DTPA-enhanced MRI performed prior to initiation 
of RFA.  
The RFA procedure was performed percutaneously under conscious sedation. We 
used real-time ultrasound guidance (Power Vision 8000, Aplio XV, Aplio XG, or Aplio 
500; Toshiba, Tokyo, Japan) during insertion of the electrode. A 17-gage cooled-tip 
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electrode (Cool-Tip; RF Ablation System, Covidien, Boulder, Colombia, CO) was 
inserted into the tumor through the liver tissue, and then radiofrequency energy was 
delivered for 6–15 min in each application. After one to two sessions of RFA, dynamic 
computed tomography (CT) or Gd-EOB-DTPA-enhanced MRI was performed to 
evaluate the efficacy of RFA. During treatment assessment, we compared imaging 
findings for early, portal venous, and late phases prior to ablation and portal venous and 
late phases following ablation. A lesion was judged to be completely ablated when the 
non-enhanced area appearing in the portal venous or late phase of CT or MRI postablation 
covered the entire lesion shown in all early, portal venous, and late phases of CT or MRI 
preablation with a safety margin in the surrounding liver parenchyma [17]. To reduce 
local recurrence after RFA, we consider a safety of at least 5 mm. 
 
Gd-EOB-DTPA-enhanced MRI before intimal RFA 
Gd-EOB-DTPA-enhanced MRI was performed prior to RFA for the diagnosis and 
staging of HCC in all patients. MRI was performed using a 1.5-T scanner (Intera Achieva 
1.5 T Nova Dual; Philips Healthcare) with a six-channel phased-array coil as the receiver 
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coil, a 1.5-T scanner (Signa HDxt; GE Healthcare), or a 3-T scanner (Discovery MR 750; 
GE Healthcare) with a twelve-channel Torso-array coil. We obtained T1-weighted dual 
fast field echo images (in-phase and opposed phase) before injecting the contrast medium. 
Dynamic fat-suppressed T1-weighted 3D turbo field-echo images were obtained before 
and 23 s (arterial phase), 80 s (portal venous phase), 240 s (late dynamic phase), and 20 
min (hepatobiliary phase) after the administration of the contrast agent. Breath-hold 
multi-shot T2-weighted images and single shot spin-echo echo-planar diffusion-weighted 
images (DWI) were obtained in the interval of the dynamic study. Patients received 0.025 
mmol/kg body weight of gadoxetic acid (EOB Primovist; Bayer Health Yakuhin Co., Ltd., 
Osaka, Japan) at a rate of 2 mL/s through a cubital venous catheter, which was flushed 
with 20 mL of saline using a power injector. 
 
Imaging analysis 
Pretreatment Gd-EOB-DTPA-enhanced MRI, including enhanced T1- and T2-weighted 
images, DWI, dynamic imaging including arterial, portal venous, and late dynamic phases, 
as well as HBPI were retrospectively reviewed by two hepatologists specialized in HCC 
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(To note, our hepatologists collectively have 13 years of experience with reading Gd-
EOB-DTPA-enhanced MRIs). First, the reviewers evaluated the HBPI and detected 
hypointense nodules in the liver. For these nodules, the relative enhanced degree of the 
nodules on the arterial phase images was determined with regard to whether or not 
hyperintensity was present. Hemangiomas and hepatic cyst identified based on classical 
enhancement pattern or nonenhancement on dynamic phase images and hyperintensity 
on T2-weighted MR images, respectively, were excluded. When imaging assessment was 
discordant between the two reviewers, consensus was obtained through discussion. 
 
Follow-up and assessment of recurrence 
During follow-up, tumor markers, including alfa fetoprotein (AFP) and des-γ-carboxy 
prothrombin, were measured every 1–2 months, and dynamic CT or Gd-EOB-DTPA-
enhanced MRI was performed every 4–6 months. In case of suspected recurrence, at least 
two radiological imaging examinations, including dynamic CT, Gd-EOB-DTPA-
enhanced MRI, contrast enhanced ultrasound (US), and/or angiographic CT, were 
performed to confirm diagnosis.  
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In this study, the development of recurrence was further defined as local recurrence, 
intrahepatic distant recurrence, hypervascularization, or extrahepatic recurrence. Local 
recurrence was defined as the reappearance of enhancing tumor tissue adjacent to the 
ablation zone after the achievement of treatment success [18]. Intrahepatic distant 
recurrence was defined as the development of new hypervascular tumors, which were not 
classified as non-hypervascular hypointense nodules on HBPI from pretreatment Gd-
EOB-DTPA-enhanced MRI and were not adjacent to the treated site. An emerging non-
hypervascular hypointense nodule detected via Gd-EOB-DTPA-enhanced MRI at the 
follow-up assessment was not defined as intrahepatic distant recurrence until 
hypervascularization was confirmed. Hypervascularization of non-hypervascular 
hypointense nodules on HBPI of pre-RFA Gd-EOB-MRI-enhanced MRI was defined as 
nodules that showed hypervascularity in arterial phase images and hypovascularity in 
portal venous or late phase images on at least two radiological imaging examinations, 
including dynamic CT, Gd-EOB-DTPA-enhanced MRI, contrast-enhanced US, and/or 
angiographic CT [12, 13]. The appearance of extrahepatic metastasis was also assessed 
on follow-up imaging. 
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We also categorized intrahepatic distant recurrence as being subsegmentally either 
identical or different relative to the subsegment of the original nodules. In this study, 
subsegments 1–8 correspond to the Couinaud’s segments 1–8, respectively according to 
the General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Third 
English Edition [19]. When a tumor was located in two or more subsegments, the 
subsegment involving the major part of the tumor was considered.  
 
Statistical analysis 
The cumulative incidence of each type of recurrence was estimated using the Kaplan–
Meier method. Time to intrahepatic distant recurrence was defined as the period from 
initial RFA until the diagnosis of such recurrence. If extrahepatic metastasis was observed 
before intrahepatic distant recurrence, the censoring date was defined as the last date of 
radiological assessment not showing such evidence of recurrence. If local recurrence or 
hypervascularization was treated by resection or local ablation, we continued follow-up 
until the initial intrahepatic distant recurrence. If local recurrence or hypervascularization 
was treated by other therapies, such as Tranarterial chemoembolization, the censoring 
14 
 
date was defined as the last date of radiological assessment. Time to hypervascularization 
was defined as the period from initial RFA until the diagnosis of hypervascularization.  
Univariate and multivariate Cox proportional-hazard regression models were used 
to estimate the hazard ratios for risk factors in relation to each type of recurrence. A p 
value of <0.05 was considered statistically significant. All statistical analyses were 
performed using SPSS statistical software (version 22; SPSS-IBM, Chicago, IL, USA). 
In multivariate analyses, we used the stepwise regression program. All variables indicated 
in the tables were included in the multivariate analysis. The results are demonstrated in 
the Tables. 
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Results 
 
Patient characteristics at baseline 
Between February 2008 and December 2012, 188 patients with HCC who received RFA 
for initial treatment of HCC were identified for potential inclusion in this study 
(Supplementary Fig. 1). Of the 132 patients who were eventually included in the study, 
the majority of patients were male (67%), Hepatitis C virus (HCV)-RNA-positive (67%), 
Child–Pugh class A (83%), and the median age was 72 years (range, 52–83) (Table 1). In 
56 patients (42%), non-hypervascular hypointense nodules were detected on HBPI from 
pretreatment Gd-EOB-DTPA-enhanced MRI. 
 
Intrahepatic distant recurrence after RFA according to non-hypovascular hypointense 
nodules 
Sixty-eight patients (52%) developed intrahepatic distant recurrence during the follow-
up period (median follow-up, 24.6 months (range, 1.0–70.7 months). In the 56 patients 
with non-hypervascular hypointense nodules, the estimated 1-, 2-, 3-, and 5-year 
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cumulative recurrence rates were 22.5, 52.1, 69.0, and 89.1%, respectively, compared 
with 7.0, 28.8, 38.7, and 48.7%, respectively, in the 76 patients without non-
hypervascular hypointense nodules (Fig. 1). We also analyzed data on the identical vs. 
different subsegmental intrahepatic distant recurrence (Fig. 2). The estimated 1-, 2-, 3-, 
and 5-year cumulative identical subsegmental intrahepatic distant recurrence rates were 
7.4, 22.1, 33.5, and 56.6%, respectively, in patients with non-hypervascular hypointense 
nodules, compared with 1.5, 11.0, 12.8, and 23.1%, respectively, in patients without non-
hypervascular hypointense nodules (Fig. 2A). On the other hand, the estimated 1-, 2-, 3-, 
and 5-year cumulative different subsegmental intrahepatic distant recurrence rates were 
20.6, 48.3, 67.3, and 83.4%, respectively, in patients with non-hypervascular hypointense 
nodules, compared with 5.6, 19.5, 32.9, and 39.6%, respectively, in patients without non-
hypervascular hypointense nodules (Fig. 2B). Multivariate analysis showed that the 
cumulative incidence of intrahepatic distant recurrence was significantly higher in 
patients with non-hypervascular hypointense nodules than in patients without non-
hypervascular hypointense nodules (Table 2). Similarly, non-hypervascular hypointense 
nodules on HBPI from pretreatment Gd-EOB-DTPA-enhanced MRI was an independent 
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risk factor of both the identical and different subsegmental intrahepatic distant recurrence 
(Supplementary Tables 1 and 2). 
 
Non-hypervascular hypointense nodules and hypervascularization 
The agreement rate of detecting non-hypervascular hypointense nodules via pretreatment 
Gd-EOB-DTPA-enhanced MRI between the two reviewers was 76.5% (101 of 132 
patients). The remaining 31 patients required consensus between the two reviewers. 
Consequently, we confirmed 56 patients with non-hypervascular hypointense nodules, 
and we determined a total of 127 non-hypervascular hypointense nodules with a median 
size of 8 mm (range: 3-17 mm). According to follow-up radiological assessment of these 
56 patients, there was an 82.1% agreement rate between the two reviewers. In the follow-
up period, 30 patients (46 nodules) developed the hypervascularization of non-
hypervascular hypointense nodules as detected by pretreatment Gd-EOB-DTPA enhanced 
MRI (a typical case is shown in Figure 3). The 1-, 2-, 3-, and 5-year hypervascularization 
rates were 26.1, 51.9, 57.7, and 65.4%, respectively. The median time of progression to 
hypervascularization was 22.4 months (95% CI, 7.7–37.1 months; Supplementary Fig. 2). 
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Table 3 shows the multivariate analysis of risk factors for hypervascularization in 56 
patients with non-hypervascular hypointense nodules on HBPI from pretreatment Gd-
EOB-DTPA-enhanced MRI. The maximum size of non-hypervascular hypointense 
nodules (>10 mm) was an independent predictive factor of hypervascularization.  
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Discussion 
 
The present study showed that non-hypervascular hypointense nodules on HBPI from 
pretreatment Gd-EOB-DTPA enhanced MRI represent a risk factor of HCC intrahepatic 
distant recurrence. Our findings confirm observations from other investigations, 
extending these in several important directions. As established by the significant studies 
of Toyoda et al. and Lee et al., non-hypervascular hypointense nodules are at a higher 
risk of recurrence after curative therapy of HCC such as hepatectomy or RFA [14, 15]. 
Unlike previous studies, we classified post-RFA recurrence as intrahepatic distant 
recurrence occurring in the liver parenchyma and hypervascularization of non-
hypervascular hypointense nodules on HBPI of pre-treatment Gd-EOB-DTPA-enhanced 
MRI. Our results indicate that livers with non-hypervascular hypointense nodules have a 
high potential of carcinogenesis. 
Carcinogenesis and spread from the primary tumor are widely believed to represent 
the two major mechanisms underlying intrahepatic recurrence of HCC [20]. The diseased 
liver undergoes carcinogenesis (i.e., de novo recurrence) and dissemination of the 
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remnant tumor cells related to the primary tumor after curative therapy, leading to 
intrahepatic metastasis. Toyoda et al. indicated that the presence of non-hypervascular 
hypointense nodule was a risk factor for multicentric occurrence but not for intrahepatic 
metastasis, which was defined based on the radiological location and pathological 
examination of recurring nodules relative to non-hypervascular hypointense nodules [14]. 
The high risk of multicentric occurrence is attributed to the high potential of 
carcinogenesis. According to Toyoda’s study, hypervascularization of non-hypervascular 
hypointense nodules was classified as multicentric occurrence [14]. In contrast, we 
focused on intrahepatic distant recurrence, leaving out hypervascularization of non-
hypervascular hypointense nodules. Intrahepatic distant recurrence in our approach was 
defined as recurrence in the liver parenchyma that lacked non-hypervascular hypointense 
nodules at pre-RFA. Specifically, intrahepatic distant recurrence included multicentric 
occurrence, except for the hypervascularization of non-hypervascular hypointense 
nodules at baseline and intrahepatic metastasis. As our study lacked pathological 
examination data, we could not classify multicentric occurrence and intrahepatic 
metastasis as well as the previous report did. This is a limitation of our study.  
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Conversely, hepatogenous spread of cancer cells may correlate with the local portal 
venous system, and notably, intrahepatic metastasis mainly occurs at the subsegment 
identical to that of the primary tumor. Based on this idea, anatomical resection involving 
the systemic removal of the hepatic spread contained in the tumor tissue is considered 
preferable [21, 22]. Thus, the risk of developing recurrence in the identical and different 
subsegments was separately analyzed in this study. Non-hypervascular hypointense 
nodules were found to be associated with a higher rate of intrahepatic distant recurrence 
at not only the different subsegment but also the identical subsegment. Taken together, 
differences in the incidence of intrahepatic distant recurrence between patients with or 
without non-hypervascular hypointense nodules was most likely not due to intrahepatic 
metastasis but due to potential carcinogenesis. Our results document the importance that 
patients with non-hypervascular hypointense nodules have high incidence of not only 
hypervascularizaiton but also intrahepatic distant recurrence. This information will be 
clinically useful during follow-up after RFA. 
In this study, the incidence of non-hypervascular hypointense nodules on HBPI from 
Gd-EOB-DTPA-enhanced MRI (42%, 56/132) does not concur with that identified in 
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previous studies (Toyoda et al.: 23%, 18/77; Lee et al.: 79%, 110/139) [14, 15]. We 
consider that these differences might be caused by disease etiology and treatment 
procedures (resection/RFA) of the study patients. The etiology linked to HCC in the 
patients included in our study was HCV infection, whereas the etiology in the previous 
study by Lee et al. was HBV infection [15]. In general, liver function, tumor size, and 
tumor number are all taken into account when choosing between resection and RFA [16]. 
Selection bias might affect the rate of non-hypervascular hypointense nodules developing 
in the study population. On the other hand, the cumulative hypervascularization rate of 
non-hypervascular hypointense nodules in this study is similar to that found of previous 
studies [12, 13]. This result suggests that the method for the detection of non-
hypervascular hypointense nodules in our study was appropriate.  
Our study had several other limitations in addition to its inability to distinguish 
between multicentric occurrence and intrahepatic metastasis. First, this study was based 
on a retrospective analysis, and thus, there may be selection bias of patients and 
differences in the interval of follow-up radiological assessments. Additionally, the 
number of patients was small, and this study was limited to HCC patients treated by RFA. 
23 
 
To note, this study was not able to assess overall survival due to a small observation 
period. Large scale, multicenter, and prospective studies with longer observation periods 
to assess the dynamics of non-hypervascular hypointense nodules detected via Gd-EOB-
DTPA-enhanced-MRI are warranted. 
This study confirms that rigorous and careful follow-up after treatment are required 
to enable the identification of not only the hypervascularization of non-hypervascular 
hypointense nodules but also intrahepatic distant recurrence for patients presenting with 
non-hypervascular hypointense nodules on HBPI from pretreatment Gd-EOB-DTPA 
enhanced MRI. Furthermore, the finding that livers with non-hypervascular hypointense 
nodules have a high potential of intrahepatic distant recurrence supports the view that 
current post-curative therapies, including the early detection of hypervascularization of 
non-hypervascular hypointense nodules and intervention, are insufficient. Treatment 
strategies that deteriorate a potential of carcinogenesis (i.e., nucleos(t)ide analogues for 
HBV or interferon-free direct acting antivirals for HCV) should be considered for these 
patients [23-25].  
  In conclusion, the presence of non-hypervascular hypointense nodules on HBPI 
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from Gd-EOB-DTPA-enhanced MRI obtained prior to RFA is a significant predictive 
factor of intrahepatic distant recurrence following RFA. Observations from preprocedure 
Gd-EOB-DTPA-enhanced MRI are critical to developing post-RFA management 
strategies in patients with early-stage HCC. 
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Table 1. Demographics and characteristics of study patients 
 
Demographics/characteristics Value 
Gender ［n（%）］  
  Male 89 (67) 
  Female 43 (33) 
Age, years ［n（%）］  
  ≤72 69 (52) 
  >72 63 (48) 
 Median (range) 72 (52-83) 
HBV-DNA positive ［n（%）］  
  Absent 117 (89) 
  Present 15 (11) 
HCV-RNA positive ［n（%）］  
  Absent 44 (33) 
  Present 88 (67) 
Alcohol abuse ［n（%）］  
  Absent 120 (91) 
  Present 12 (9) 
Cirrhosis ［n（%）］  
  Absent 28 (21) 
  Present 104 (79) 
Child–Pugh class ［n（%）］  
  A 109 (83) 
  B 23 (17) 
AST ［n（%）］  
  ≤3.0×UNL 114 (86) 
  >3.0×UNL 18 (14) 
AFP ［n（%）］  
  ≤100 112 (85) 
  >100 20 (15) 
Tumur size of hypervascular HCC, mm  
Maximum diameter，> 20 ［n（%）］  
  Absent 85（64） 
  Present 47（36） 
  Median (range) 19 (6-40) 
Tumor number of hypervascular HCC，multiple ［n（%）］  
  Absent 95 (72) 
  Present 37 (28) 
Non-hypervascular hypointense nodule on HBPI ［n（%）］  
  Absent 76（58） 
  Present 56（42） 
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, alpha-
fetoprotein; HCC, hepatocellular carcinoma; HBPI, hepatobiliary phase image 
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Table 2. Uni- and multivariate analyses of intrahepatic distant recurrence following radiofrequency ablation 
 
Variables 
  Univariate analysis 
p 
Multivariate analysis 
p 
n（%） 
Hazard 
ratio 
95% C.I. 
Hazard 
ratio 
95% C.I. 
Gender, male         
   Absent 89 (67) Reference      
   Present 43 (33) 0,975 0.592-1.606 0.921    
Age >72 years         
   Absent 69 (52) Reference      
   Present 63 (48) 1.168 0.725-1.883 0.523    
HBV-DNA positive         
   Absent 117 (89) Reference      
   Present 15 (11) 0.753 0.325-1.744 0.508    
HCV-RNA positive         
   Absent 44 (33) Reference      
   Present 88 (67) 1.382 0.825-2.315 0.220    
Alcohol abuse         
 Absent 120 (91) Reference      
 Present 12 (9) 1.065 0.509-2.232 0.867    
Child-Pugh class B         
   Absent 109 (83) Reference   Reference   
   Present 23 (17) 2.104 1.164-3.804 0.014 2.304 1.272-4.174 0.006 
AST, >3 × UNL         
   Absent 114 (86) Reference      
   Present 18 (14) 1.348 0.686-2.649 0.386    
AFP, >100 ng/mL         
   Absent 112 (85) Reference      
   Present 20 (15) 1.733 0.927-3.241 0.085    
Maximum tumor size，
>20mm  
       
  Absent 85（64） Reference      
  Present 47（36） 0.800 0.481-1.330 0.389    
Tumor number，multiple         
  Absent 95 (72) Reference      
  Present 37 (28) 2.016 1.203-3.379 0.008    
Non-hypervascular 
hypointense nodule  
       
   Absent 76(58) Reference   Reference   
   Present 56(42) 2.763 1.696-4.502 <0.001 2.87 1.759-4.681 
<0.00
1 
Abbreviations:  HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, 
alpha-fetoprotein 
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Table 3. Uni- and multivariate analyses of the hypervascularization of non-hypervascular hypointense 
nodules 
 
Variables 
  Univariate analysis p Multivariate analysis p 
n（%） Hazard ratio 95% C.I.  Hazard ratio 95% C.I.  
Gender, male         
   Male 36（72） Reference      
   Female 20（28） 0,889 0.427-1.847 0.752    
Age >72 years         
   Absent 30（54） Reference      
   Present 26（46） 0.462 0.356-1.599 0.523    
HBV-DNA positive         
   Absent 47（84） Reference      
   Present 9（16） 0.879 0.335-2.304 0.793    
HCV-RNA positive         
   Absent 20（28） Reference      
   Present 36（72） 0.933 0.433-1.965 0.855    
Alcohol abuse         
 Absent 54 (96) Reference      
 Present 2 (4) 1.740 0.408-7.425 0.454    
Child-Pugh class B         
   Absent 48（86） Reference      
   Present 8（14） 0.979 0.341-2.813 0.969    
AST, >3 × UNL         
   Absent 46（82） Reference      
   Present 10（18） 1.122 0.457-2.751 0.802    
AFP, >100 ng/ml         
   Absent 45（80） Reference      
   Present 11（20） 2.420 1.095-5.347 0.029    
Maximun tumor size of 
hypervascular HCC，>20mm  
       
  Absent 37（66） Reference      
  Present 19（34） 0.840 0.382-1.844 0.663    
Tumor number of 
hypervascular HCC，multiple  
       
  Absent 39（70） Reference      
  Present 17（30） 1.772 0.839-3.741 0.134    
Maximum tumor size of 
hypointense nodule, >10mm  
       
   Absent 34 (61) Reference   Reference   
   Present 22 (39) 2.942 1.419-6.101 0.004 2.942 1.419-6.101 0.004 
Tumor number of 
hypointense nodule  
       
   Absent 26 (46) Reference      
   Present 30 (54) 1.214 0.589-2.504 0.600       
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, alpha-
fetoprotein; HCC, hepatocellular carcinoma 
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Figure 1. Kaplan–Meier curve of cumulative intrahepatic distant recurrence (blue 
line: presece of non-hypervascular hypointense nodules, red line: absence of  non-
hypervascular hypointense nodules). 
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Figure 2. Kaplan–Meier curve of cumulative intrahepatic distant recurrence (blue 
line: presece of non-hypervascular hypointense nodules, red line: absence of  non-
hypervascular hypointense nodules) . A: Rates of intrahepatic distant recurrence at 
the identical subsegment in patients with or without concurrent non-hypervascular 
hypointense nodules detected during the HBPI of pre-RFA Gd-EOB-DTPA-enhanced 
MRI. B: Rates of intrahepatic distant recurrence at different subsegments in patients 
with or without concurrent non-hypervascular hypointense nodules detected during the 
HBPI of pre-RFA Gd-EOB-DTPA-enhanced MRI.  
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Figure 3. A representative case of hypervascularization of non-hypervascular 
hypointense nodules in patients with hepatocellular carcinoma as detected by 
gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) 
enhanced MRI. A 61-year-old male received radiofrequency ablation (RFA) as an 
initial treatment for hepatocellular carcinoma (A: arterial image and B: hepatobiliary 
phase image (HBPI) of preprocedural Gd-EOB-DTPA-enhanced MRI). Non-
hypervascular hypointense nodules were observed in another site of the liver 
parenchyma from which we performed RFA. Twenty-one months after RFA (C: arterial 
image and D: HBPI of preprocedural Gd-EOB-DTPA-enhanced MRI), 
hypervascularization was detected in the arterial image.
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Supplementary Table 1. Uni- and multivariate analyses of identical subsegmental intrahepatic distant 
recurrence following radiofrequency ablation 
 
Variables 
  Univariate analysis 
p 
Multivariate analysis 
p 
n（%） 
Hazard 
ratio 
95% C.I. 
Hazard 
ratio 
95% C.I. 
Gender, male         
   Absent 89 (67) Reference      
   Present 43 (33) 0.956 0.457-2.002 0.906    
Age >72 years         
   Absent 69 (52) Reference      
   Present 63 (48) 1.012 0.497-2.060 0.975    
HBV-DNA positive         
   Absent 117 (89) Reference      
   Present 15 (11) 1.417 0.542-3.705 0.477    
HCV-RNA positive         
   Absent 44 (33) Reference      
   Present 88 (67) 0.888 0.431-1.832 0.749    
Alcohol abuse         
 Absent 120 (91) Reference      
 Present 12 (9) 0.882 0.268-2.907 0.837    
Child-Pugh class B         
   Absent 109 (83) Reference   Reference   
   Present 23 (17) 3.190 1.464-6.954 0.004 3.474 1.570-7.688 0.002 
AST, >3 × UNL         
   Absent 114 (86) Reference      
   Present 18 (14) 0.759 0.230-2.509 0.651    
AFP, >100 ng/mL         
   Absent 112 (85) Reference   Reference   
   Present 20 (15) 4.686 2.186-10.046 <0.001 5.609 2.473-12.722 <0.001 
Maximum tumor size，
>20mm  
       
  Absent 85（64） Reference   Reference   
  Present 47（36） 0.525 0.226-1.219 0.134 0.420 0.174-1.010 0.053 
Tumor number，multiple         
  Absent 95 (72) Reference      
  Present 37 (28) 2.321 1.122-4.801 0.023    
Non-hypervascular 
hypointense nodule  
       
   Absent 76(58) Reference   Reference   
   Present 56(42) 2.980 1.423-6.239 0.004 2.365 1.100-5.082 0.027 
Abbreviations:  HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, alpha-
fetoprotein 
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Supplementary Table 2. Uni- and multivariate analyses of different subsegmental intrahepatic distant 
recurrence following radiofrequency ablation 
 
Variables 
  Univariate analysis 
p 
Multivariate analysis 
p 
n（%） 
Hazard 
ratio 
95% C.I. 
Hazard 
ratio 
95% C.I. 
Gender, male         
   Absent 89 (67) Reference      
   Present 43 (33) 1.091 0.637-1.867 0.752    
Age >72 years         
   Absent 69 (52) Reference      
   Present 63 (48) 1.124 0.679-1.860 0.649    
HBV-DNA positive         
   Absent 117 (89) Reference      
   Present 15 (11) 0.612 0.245-1.531 0.294    
HCV-RNA positive         
   Absent 44 (33) Reference   Reference   
   Present 88 (67) 1.668 0.952-2.924 0.074 1.907 1.081-3.364 0.026 
Alcohol abuse         
 Absent 120 (91) Reference      
 Present 12 (9) 1.029 0.468-2.265 0.943    
Child-Pugh class B         
   Absent 109 (83) Reference   Reference   
   Present 23 (17) 1.785 0.947-3.365 0.073 2.189 1.150-4.163 0.017 
AST, >3 × UNL         
   Absent 114 (86) Reference      
   Present 18 (14) 1.626 0.821-3.220 0.163    
AFP, >100 ng/mL         
   Absent 112 (85) Reference      
   Present 20 (15) 1.107 0.545-2.249 0.778    
Maximum tumor size，
>20mm  
       
  Absent 85（64） Reference      
  Present 47（36） 0.797 0.463-1.370 0.411    
Tumor number，multiple         
  Absent 95 (72) Reference      
  Present 37 (28) 1.329 0.758-2.331 0.321    
Non-hypervascular 
hypointense nodule  
       
   Absent 76(58) Reference   Reference   
   Present 56(42) 3.108 1.840-5.248 <0.001 3.276 1.937-5.540 <0.001 
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, alpha-
fetoprotein
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Supplementary Figure 1. Study flow. 
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Supplementary Figure 2. Kaplan–Meier curve of the cumulative 
hypervascularization rate of non-hypervascular hypointense nodules on pre-RFA 
HBPI of Gd-EOB-DTPA-enhanced MRI. 
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